Morgan Stanley analyst Matthew Harrison is out with a research note on shares of Celgene Corporation (NASDAQ:CELG) on the heels of hosting a lunch …
The state of Colorado has just announced it will be loosening restrictions for Medicaid Hepatitis C patients, which could translate to an increase …
Morgan Stanley analyst Matthew Harrison provides commentary on Celgene Corporation (NASDAQ:CELG) ahead of topline data due for its pipeline oral Crohn’s drug GED-0301 …
Drug giant Celgene Corporation (NASDAQ:CELG) just came in strong this second quarter, thanks to great performances from pipeline drugs lymphoma treating Revlimid and Pomalyst, …
In a research report entitled, “Why HCV Sales Could Miss Consensus”, Morgan Stanley analyst Matthew Harrison today reiterated an Equal-weight rating on shares of Gilead Sciences (NASDAQ:GILD), …
